Cited by 366Monoclonal and Polyclonal Antibodies ResearchRespiratory viral infections researchBiosimilars and Bioanalytical Methods

The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.

A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults

Open access

Robbie, Gabriel J., Criste, Ryan, Dall'Acqua, William F., Jensen, Kathryn, Patel, Nita K., Losonsky, Genevieve A., Griffin, M. Pamela·2013·Antimicrobial Agents and Chemotherapy

DOI 10.1128/aac.01285-13PMC PMC3837853

Open this paper in CoChat — free account

Abstract

The study objective was to evaluate the pharmacokinetics (PK), antidrug antibody (ADA), and safety of motavizumab-YTE (motavizumab with amino acid substitutions M252Y/S254T/T256E [YTE]), an Fc-modified anti-respiratory syncytial virus (RSV) monoclonal antibody. Healthy adults ( n = 31) were randomized to receive a single intravenous (i.v.) dose of motavizumab-YTE or motavizumab (0.3, 3, 15, or 30 mg/kg) and followed for 240 days. Clearance of motavizumab-YTE was significantly lower (71% to 86%) and the half-life ( t 1/2 ) was 2- to 4-fold longer than with motavizumab. However, similar peak concentrations and volume-of-distribution values, indicative of similar distribution properties, were seen at all dose levels. The sustained serum concentrations of motavizumab-YTE were fully functional, as shown by RSV neutralizing activity that persisted for 240 days with motavizumab-YTE versus 90 days postdose for motavizumab. Safety and incidence of ADA were comparable between groups. In this first study of an Fc-modified monoclonal antibody in humans, motavizumab-YTE was well tolerated and exhibited an extended half-life of up to 100 days. (This study has been registered at ClinicalTrials.gov under registration no. NCT00578682.)

Integrity signals

Registry

Crossref · 10.1128/aac.01285-13

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
The Burden of Respiratory Syncytial Virus Infection in Young Children
Hall, C. B., Weinberg, G. A., Iwane, M. K., Blumkin, A. K., Edwards, K. M., Staat, M. A., Auinger, P., Griffin, M. R., Poehling, K. A., Erdman, D. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0804877 · Cited by 2,250
Self-citation
Report of the Committee on Infectious Diseases
Nider, H. (1989) · Archives of Dermatology · doi:10.1001/archderm.1989.01670190156031 · Cited by 1,911
An Fc receptor structurally related to MHC class I antigens
Simister, N. E., & Mostov, K. E. (1989) · Nature · doi:10.1038/337184a0 · Cited by 729
Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)
Dall’Acqua, W. F., Kiener, P. A., & Wu, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604292200 · Cited by 648
Self-citation
Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR
Suzuki, T., Ishii‐Watabe, A., Tada, M., Kobayashi, T., Kanayasu‐Toyoda, T., Kawanishi, T., & Yamaguchi, T. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903296 · Cited by 375
Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract
Wu, H., Pfarr, D. S., Johnson, S., Brewah, Y. A., Woods, R. M., Patel, N., White, W. I., Young, J. F., & Kiener, P. A. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.02.024 · Cited by 374
Self-citation
Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences
Acqua, W. F. D., Woods, R. M., Ward, E. S., Palaszynski, S., Patel, N., Brewah, Y. A., Wu, H., Kiener, P. A., & Langermann, S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.5171 · Cited by 370
Self-citation
Isolation and characterization of an Fc receptor from neonatal rat small intestine
Simister, N. E., & Rees, A. R. (1985) · European Journal of Immunology · doi:10.1002/eji.1830150718 · Cited by 341
Neonatal Fc receptor and IgG-based therapeutics
Kuo, T. T., & Aveson, V. G. (2011) · mAbs · doi:10.4161/mabs.3.5.16983 · Cited by 243

Show all 18 references

Research works printed but not linked: 2

FaggioniR YaoZ LiangM SchneiderA VainshteinI LeeR RoskosL. 2010. Effect of the YTE mutation on the PK/PD of MEDI5117, abstr T2091. Abstr. Am. Assoc. Pharm. Sci. Natl. Biotechnol. Conf., San Francisco, CA, 17 to 19 May 2010. American Association of Pharmaceutical Scientists, Arlington, VA.
YuX IciekL CristeR SellmanB StoverC JafriH EsserM RoskosL RobbieG. 2013. Modeling of pharmacokinetics (PK) of a YTE-monoclonal antibody targeting Staphylococcus aureus alpha toxin in cynomolgus monkeys: human PK prediction, abstr T2123. Abstr. Am. Assoc. Pharm. Sci. Natl. Biotechnol. Conf., San Francisco, CA, 17 to 19 May 2010. American Association of Pharmaceutical Scientists, Arlington, VA.

Sorted by citations

Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection
Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y., Murray, D. L., Orenstein, W. A., Rathore, M. H., Sawyer, M. H., et al. (2014) · PEDIATRICS · doi:10.1542/peds.2014-1665 · Cited by 769
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants
Griffin, M. P., Yuan, Y., Takas, T., Domachowske, J. B., Madhi, S. A., Manzoni, P., Simões, E. A. F., Esser, M. T., Khan, A. A., Dubovsky, F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913556 · Cited by 810
Self-citation
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 780
Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
Levin, M. J., Ustianowski, A., Wit, S. D., Launay, O., Avila, M., Templeton, A., Yuan, Y., Seegobin, S., Ellery, A., Levinson, D. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116620 · Cited by 694
Malaria
Phillips, M. A., Burrows, J. N., Manyando, C., van Huijsduijnen, R. H., Voorhis, W. C. V., & Wells, T. N. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.50 · Cited by 648
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 711
The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates
Mazur, N. I., Higgins, D., Nunes, M. C., Melero, J. A., Langedijk, A. C., Horsley, N., Buchholz, U. J., Openshaw, P., McLellan, J. S., Englund, J. A., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30292-5 · Cited by 462
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
Liming, L. (2017) · Protein & Cell · doi:10.1007/s13238-017-0408-4 · Cited by 407
Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
Ko, S., Pegu, A., Rudicell, R. S., Yang, Z., Joyce, M. G., Chen, X., Wang, K., Bao, S., Kraemer, T. D., Räth, T., et al. (2014) · Nature · doi:10.1038/nature13612 · Cited by 381
Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection
Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y., Murray, D. L., Orenstein, W. A., Rathore, M. H., Sawyer, M. H., et al. (2014) · PEDIATRICS · doi:10.1542/peds.2014-1666 · Cited by 384
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
Zhu, Q., McLellan, J. S., Kallewaard, N. L., Ulbrandt, N. D., Palaszynski, S., Zhang, J., Moldt, B., Khan, A. A., Svabek, C., McAuliffe, J. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj1928 · Cited by 368
Self-citation
IgG Fc engineering to modulate antibody effector functions
Wang, X., Mathieu, M., & Brezski, R. J. (2018) · Protein & Cell · doi:10.1007/s13238-017-0473-8 · Cited by 356
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
Saunders, K. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01296 · Cited by 321
Considerations for the Design of Antibody-Based Therapeutics
Goulet, D. R., & Atkins, W. M. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.031 · Cited by 328
Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development
Ovacik, M., & Lin, K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12567 · Cited by 299
Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics
Mazur, N. I., Martinón‐Torres, F., Baraldi, E., Fauroux, B., Greenough, A., Heikkinen, T., Manzoni, P., Mejías, A., Nair, H., Papadopoulos, N. G., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00255-6 · Cited by 303
The therapeutic age of the neonatal Fc receptor
Pyzik, M., Kozicky, L. K., Gandhi, A. K., & Blumberg, R. S. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00821-1 · Cited by 288
Current progress in innovative engineered antibodies
Strohl, W. R. (2017) · Protein & Cell · doi:10.1007/s13238-017-0457-8 · Cited by 296
Monoclonal antibody therapies against SARS-CoV-2
Focosi, D., McConnell, S. A., Casadevall, A., Cappello, E., Valdiserra, G., & Tuccori, M. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00311-5 · Cited by 274
Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms
Oganesyan, V., Damschroder, M. M., Cook, K. E., Li, Q., Gao, C., Wu, H., & Dall'Acqua, W. F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.537563 · Cited by 259
Self-citation
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals
Bar‐On, Y., Gruell, H., Schoofs, T., Pai, J. A., Nogueira, L., Butler, A. L., Millard, K. G., Lehmann, C., Suárez, I., Oliveira, T. Y., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0186-4 · Cited by 267
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
Gaudinski, M. R., Coates, E. E., Houser, K. V., Chen, G. L., Yamshchikov, G. V., Saunders, J. G., Holman, L. A., Gordon, I. J., Plummer, S. H., Hendel, C. S., et al. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002493 · Cited by 235
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Hwang, Y., Lu, R., Su, S.-C., Chiang, P.-Y., Ko, S.-H., Ke, F.-Y., Liang, K.-H., Hsieh, T.-Y., & Wu, H. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-021-00784-w · Cited by 247
The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy
Sockolosky, J. T., & Szoka, F. C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.02.005 · Cited by 253
Aptamer Therapeutics in Cancer: Current and Future
Morita, Y., Leslie, M., Kameyama, H., Volk, D. E., & Tanaka, T. (2018) · Cancers · doi:10.3390/cancers10030080 · Cited by 219
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
Loo, Y., McTamney, P. M., Arends, R. H., Gasser, R. A., Abram, M. E., Cheng, L., Diallo, S., Flores, D. J., Bond, N. J., Ren, K., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl8124 · Cited by 221
Half-life extended biotherapeutics
Kontermann, R. E. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1165661 · Cited by 197
Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial
O’Brien, K. L., Chandran, A., Weatherholtz, R., Jafri, H. S., Griffin, M. P., Bellamy, T., Millar, E. V., Jensen, K. M., Harris, B., Reid, R., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00247-9 · Cited by 190
Self-citation
Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
Marshall, M. J. E., Stopforth, R. J., & Cragg, M. S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01245 · Cited by 190
Antibody therapies for the prevention and treatment of viral infections
Salazar, G. T., Zhang, N., Fu, T., & An, Z. (2017) · npj Vaccines · doi:10.1038/s41541-017-0019-3 · Cited by 171
Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection
Resch, B. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1337614 · Cited by 156
Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies
Kamath, A. V. (2016) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2016.09.004 · Cited by 164
Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy
Almagro, J. C., Daniels‐Wells, T. R., Pérez‐Tapia, S. M., & Penichet, M. L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01751 · Cited by 165
A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies
Kumari, M., Lu, R., Li, M., Huang, J., Hsu, F., Ko, S.-H., Ke, F.-Y., Su, S.-C., Liang, K.-H., Yuan, J. P., et al. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00852-9 · Cited by 166
Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults
Griffin, M. P., Khan, A. A., Esser, M. T., Jensen, K. M., Takas, T., Kankam, M. K., Villafana, T. L., & Dubovsky, F. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01714-16 · Cited by 154
Self-citation
Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults
Yu, X., Robbie, G. J., Wu, Y., Esser, M. T., Jensen, K. M., Schwartz, H. I., Bellamy, T., Hernandez‐Illas, M., & Jafri, H. S. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01020-16 · Cited by 140
Self-citation
Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement
Abu-Raya, B., Maertens, K., Edwards, K. M., Omer, S. B., Englund, J. A., Flanagan, K. L., Snape, M. D., Amirthalingam, G., Leuridan, E. E., Damme, P. V., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01282 · Cited by 135
Impact of structural modifications of IgG antibodies on effector functions
Damelang, T., Brinkhaus, M., van Osch, T. L. J., Schuurman, J., Labrijn, A. F., Rispens, T., & Vidarsson, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1304365 · Cited by 143
malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication
Elimination, T. M. R. C. P. O. T. F. M. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002455 · Cited by 119
Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions
Abdeldaim, D. T., & Schindowski, K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102402 · Cited by 123
Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies
Avery, L. B., Wang, M., Kavosi, M. S., Joyce, A. P., Kurz, J. C., Fan, Y., Dowty, M. E., Zhang, M., Zhang, Y., Cheng, A., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1193660 · Cited by 109
Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides
Datta‐Mannan, A. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.086488 · Cited by 113
Targeting FcRn to Generate Antibody-Based Therapeutics
Ward, E. S., & Ober, R. J. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.07.007 · Cited by 112
Extending human IgG half-life using structure-guided design
Booth, B. J., Ramakrishnan, B., Narayan, K. M., Wollacott, A. M., Babcock, G. J., Shriver, Z. H., & Viswanathan, K. (2018) · mAbs · doi:10.1080/19420862.2018.1490119 · Cited by 114
Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases
Fukuzawa, T., Sampei, Z., Haraya, K., Ruike, Y., Shida-Kawazoe, M., Shimizu, Y., Gan, S. W., Irie, M., Tsuboi, Y., Tai, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01087-7 · Cited by 107
pH-dependent Binding Engineering Reveals an FcRn Affinity Threshold That Governs IgG Recycling
Borrok, M. J., Wu, Y., Beyaz, N., Yu, X., Oganesyan, V., Dall’Acqua, W. F., & Tsui, P. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.603712 · Cited by 111
Self-citation
Monoclonal Antibodies: Past, Present and Future
Posner, J., Barrington, P. J., Brier, T., & Datta‐Mannan, A. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_323 · Cited by 120
Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation
Igawa, T., Haraya, K., & Hattori, K. (2016) · Immunological Reviews · doi:10.1111/imr.12392 · Cited by 100
Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19
Sempowski, G. D., Saunders, K. O., Acharya, P., Wiehe, K. J., & Haynes, B. F. (2020) · Cell · doi:10.1016/j.cell.2020.05.041 · Cited by 102
A human endothelial cell-based recycling assay for screening of FcRn targeted molecules
Grevys, A., Nilsen, J., Sand, K. M. K., Daba, M. B., Øynebråten, I., Bern, M., McAdam, M. B., Foss, S., Schlothauer, T., Michaelsen, T. E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03061-x · Cited by 98
Antibacterial monoclonal antibodies: the next generation?
DiGiandomenico, A., & Sellman, B. R. (2015) · Current Opinion in Microbiology · doi:10.1016/j.mib.2015.07.014 · Cited by 93
Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques
Magnani, D. M., Rogers, T. F., Beutler, N., Ricciardi, M. J., Bailey, V. K., Gonzalez-Nieto, L., Briney, B. S., Sok, D., Le, K. M., Strubel, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan8184 · Cited by 92
Fifty years of monoclonals: the past, present and future of antibody therapeutics
Chan, A. C., Martyn, G. D., & Carter, P. J. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01207-9 · Cited by 104
Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy
Ghemrawi, R., Abuamer, L., Kremesh, S., Hussien, G., Ahmed, R., Mousa, W. K., Khoder, G., & Khair, M. (2024) · Biomedicines · doi:10.3390/biomedicines12092158 · Cited by 97
Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies
Glassman, P. M., & Balthasar, J. P. (2016) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-016-9482-0 · Cited by 88
An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence
Lee, C., Kang, T. H., Godon, O., Watanabe, M., Delidakis, G., Gillis, C. M., Sterlin, D., Hardy, D., Cogné, M., Macdonald, L. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13108-2 · Cited by 88
Targeting FcRn for the modulation of antibody dynamics
Ward, E. S., Devanaboyina, S. C., & Ober, R. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.02.007 · Cited by 89
A molecular understanding of alphavirus entry and antibody protection
Kim, A. S., & Diamond, M. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00825-7 · Cited by 87
Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria
Foss, S., Sakya, S. A., Aguinagalde, L., Lustig, M., Shaughnessy, J., Cruz, A. R., Scheepmaker, L. M., Mathiesen, L., Ruso‐Julve, F., Anthi, A. K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46321-9 · Cited by 88
Monoclonal antibodies: technologies for early discovery and engineering
Kennedy, P. J., Oliveíra, C., Granja, P. L., & Sarmento, B. F. C. C. (2017) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2017.1357002 · Cited by 89
Mechanisms of Neutralization of a Human Anti-α-toxin Antibody
Oganesyan, V., Peng, L., Damschroder, M. M., Li, C., Sadowska, A., Tkaczyk, C., Sellman, B. R., Wu, H., & Dall’Acqua, W. F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.601328 · Cited by 84
Self-citation
Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis
Edavettal, S. C., Cejudo–Martín, P., Dasgupta, B., Yang, D., Buschman, M. D., Domingo, D. L., Kolen, K. V., Jaiprasart, P., Gordon, R. E., Schutsky, K., et al. (2022) · Med · doi:10.1016/j.medj.2022.09.007 · Cited by 86
Fc Sialylation Prolongs Serum Half-Life of Therapeutic Antibodies
Bas, M., Terrier, A., Jacque, E., Dehenne, A., Pochet-Béghin, V., Beghin, C., Dezetter, A.-S., Dupont, G., Engrand, A., Beaufils, B., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800896 · Cited by 82
Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation
Nixon, J. V., Newbold, P., Mustelin, T., Anderson, G. P., & Kolbeck, R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.016 · Cited by 83
Smart drug delivery of p-Coumaric acid loaded aptamer conjugated starch nanoparticles for effective triple-negative breast cancer therapy
Mariadoss, A. V. A., Saravanakumar, K., Sathiyaseelan, A., Karthikkumar, V., & Wang, M. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.11.170 · Cited by 79
Therapeutic monoclonal antibodies in allergy: Targeting IgE , cytokine, and alarmin pathways
Eggel, A., Pennington, L. F., & Jardetzky, T. S. (2024) · Immunological Reviews · doi:10.1111/imr.13380 · Cited by 85
Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life
Majumdar, R., Esfandiary, R., Bishop, S. M., Samra, H. S., Middaugh, C. R., Volkin, D. B., & Weis, D. D. (2014) · mAbs · doi:10.4161/19420862.2014.985494 · Cited by 75
Coming together at the hinges: Therapeutic prospects of IgG3
Chu, T. H., Patz, E. F., & Ackerman, M. E. (2021) · mAbs · doi:10.1080/19420862.2021.1882028 · Cited by 76
MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia Model
Hua, L., Cohen, T. S., Shi, Y., Datta, V., Hilliard, J. J., Tkaczyk, C., Suzich, J., Stover, C. K., & Sellman, B. R. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00510-15 · Cited by 74
Harnessing Fc receptor biology in the design of therapeutic antibodies
Sondermann, P., & Szymkowski, D. E. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.03.005 · Cited by 75
Human monoclonal antibodies against chikungunya virus target multiple distinct epitopes in the E1 and E2 glycoproteins
Quiroz, J. A., Malonis, R. J., Thackray, L. B., Cohen, C. A., Pallesen, J., Jangra, R. K., Brown, R. S., Hofmann, D., Holtsberg, F. W., Shulenin, S., et al. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1008061 · Cited by 69
A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates
Keeffe, J. R., Rompay, K. K. A. V., Olsen, P. C., Wang, Q., Gazumyan, A., Azzopardi, S. A., Schaefer-Babajew, D. J., Lee, Y. E., Stuart, J. B., Singapuri, A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.031 · Cited by 68
A Phase 1 Randomized, Double‐Blind, Placebo‐Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK‐1654 in Healthy Adults
Aliprantis, A. O., Wolford, D. G., Caro, L., Maas, B. M., Ma, H., Montgomery, D. L., Sterling, L. M., Hunt, A., Cox, K. S., Vora, K. A., et al. (2020) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.883 · Cited by 67
Influence of Charge, Hydrophobicity, and Size on Vitreous Pharmacokinetics of Large Molecules
Crowell, S. R., Wang, K., Famili, A., Shatz-Binder, W., Loyet, K. M., Chang, V., Liu, Y., Prabhu, S., Kamath, A. V., & Kelley, R. F. (2019) · Translational Vision Science & Technology · doi:10.1167/tvst.8.6.1 · Cited by 62
A cocktail of humanized anti–pertussis toxin antibodies limits disease in murine and baboon models of whooping cough
Nguyen, A. W., Wagner, E. K., Laber, J. R., Goodfield, L. L., Smallridge, W. E., Harvill, E. T., Papin, J. F., Wolf, R. F., PADLAN, E. A., Bristol, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad0966 · Cited by 61
Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials
Broadbent, L., Groves, H. E., Shields, M. D., & Power, U. F. (2015) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12313 · Cited by 64
Tixagevimab + Cilgavimab: First Approval
Keam, S. J. (2022) · Drugs · doi:10.1007/s40265-022-01731-1 · Cited by 60
Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®
Magnenat, L., Palmese, A., Frémaux, C., D'Amici, F., Terlizzese, M., Rossi, M., & Chevalet, L. (2016) · mAbs · doi:10.1080/19420862.2016.1259046 · Cited by 59
Optimization of therapeutic antibodies
Wang, B., Kankanamalage, S. G., Dong, J., & Liu, Y. (2021) · Antibody Therapeutics · doi:10.1093/abt/tbab003 · Cited by 62
A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment
Focosi, D., & Casadevall, A. (2022) · Viruses · doi:10.3390/v14091999 · Cited by 59
Anti-Alpha-Toxin Monoclonal Antibody and Antibiotic Combination Therapy Improves Disease Outcome and Accelerates Healing in a Staphylococcus aureus Dermonecrosis Model
Hilliard, J. J., Datta, V., Tkaczyk, C., Hamilton, M. M., Sadowska, A., Jones-Nelson, O., O’Day, T. L., Weiss, W. J., Szarka, S., Nguyen, V., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03918-14 · Cited by 57
Viral infection neutralization tests: A focus on severe acute respiratory syndrome‐coronavirus‐2 with implications for convalescent plasma therapy
Focosi, D., Maggi, F., Mazzetti, P., & Pistello, M. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2170 · Cited by 59
The Highly Evolvable Antibody Fc Domain
Park, H. I., Yoon, H. W., & Jung, S. T. (2016) · Trends in biotechnology · doi:10.1016/j.tibtech.2016.04.005 · Cited by 54
Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection
Mejías, A., García-Mauriño, C., Fernández, R. R., Peeples, M. E., & Ramilo, O. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.09.026 · Cited by 55
Passive and active immunization against respiratory syncytial virus for the young and old
Villafana, T. L., Falloon, J., Griffin, M. P., Zhu, Q., & Esser, M. T. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1333425 · Cited by 53
Self-citation
In Translation: FcRn across the Therapeutic Spectrum
Qi, T., & Cao, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063048 · Cited by 59
Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging
Vivier, D., Sharma, S. K., & Zeglis, B. M. (2018) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3628 · Cited by 57
Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies
Leipold, D. D., & Prabhu, S. (2018) · Clinical and Translational Science · doi:10.1111/cts.12597 · Cited by 56
Prevention of Pediatric Respiratory Syncytial Virus Lower Respiratory Tract Illness: Perspectives for the Next Decade
Aranda, S. S., & Polack, F. P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01006 · Cited by 55
Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRnin vitroandin vivo
Mester, S., Evers, M., Meyer, S., Nilsen, J., Greiff, V., Sandlie, I., Leusen, J. H. W., & Andersen, J. T. (2021) · mAbs · doi:10.1080/19420862.2021.1893888 · Cited by 54
Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Infection
Fernández, R. R., Mejías, A., & Ramilo, O. (2021) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003121 · Cited by 55
Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions
Monnet, C., Jorieux, S., Urbain, R., Fournier, N., Bouayadi, K., de Romeuf, C., Behrens, C. K., Fontayne, A., & Mondon, P. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00039 · Cited by 52
An “Fc-Silenced” IgG1 Format With Extended Half-Life Designed for Improved Stability
Borrok, M. J., Mody, N., Lu, X., Kuhn, M. L., Wu, H., Dall’Acqua, W. F., & Tsui, P. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.12.023 · Cited by 52
Self-citation
Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life
Grevys, A., Frick, R., Mester, S., Flem-Karlsen, K., Nilsen, J., Foss, S., Sand, K. M. K., Emrich, T., Fischer, J. A. A., Greiff, V., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103746 · Cited by 51
A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state
Teranishi-Ikawa, Y., Soeda, T., Koga, H., Yamaguchi, K., Kato, K., Esaki, K., Asanuma, K., Funaki, M., Ichiki, M., Ikuta, Y., et al. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.09.034 · Cited by 51
Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody
Monnet, C., Jorieux, S., Souyris, N., Zaki, O., Jacquet, A., Fournier, N., Crozet, F., de Romeuf, C., Bouayadi, K., Urbain, R., et al. (2014) · mAbs · doi:10.4161/mabs.27854 · Cited by 54
Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults
Phuah, J. Y., Maas, B. M., Tang, A., Zhang, Y., Caro, L., Railkar, R. A., Swanson, M. D., Cao, Y., Li, H., Roadcap, B. A., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115851 · Cited by 57
Neutralization of pertussis toxin by a single antibody prevents clinical pertussis in neonatal baboons
Nguyen, A. W., DiVenere, A. M., Papin, J. F., Connelly, S., Kaleko, M., & Maynard, J. A. (2020) · Science Advances · doi:10.1126/sciadv.aay9258 · Cited by 50
Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention
Kisalu, N. K., Pereira, L. D. S., Ernste, K., Flores-García, Y., Idris, A. H., Asokan, M., Dillon, M., MacDonald, S. W., Shi, W., Chen, X., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.143958 · Cited by 48
Broadly neutralizing antibodies in HIV-1 treatment and prevention
Kumar, R., Qureshi, H., Deshpande, S., & Bhattacharya, J. (2018) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/2515135518800689 · Cited by 46

Authors: Robbie, G. J., Criste, R., Dall'Acqua, W. F., Jensen, K., Patel, N. K., Losonsky, G. A., & Griffin, M. P.
Affiliations: Clinical Pharmacology and DMPK, MedImmune, Gaithersburg, Maryland, USA
Antibody Discovery and Protein Engineering, MedImmune, Gaithersburg, Maryland, USA
Biostatistics, MedImmune, Gaithersburg, Maryland, USA
Research and Development, Infectious Disease, MedImmune, Gaithersburg, Maryland, USA
Clinical Research and Development, MedImmune, Gaithersburg, Maryland, USA
ORCID: Patel, Nita K.
Griffin, M. Pamela
Venue: Antimicrobial Agents and Chemotherapy
Publisher: American Society for Microbiology
Published: 2013-12
Volume: 57
Issue: 12
Pages: 6147-6153
ISSN: 0066-4804 (ISSN-L)
1098-6596
DOI: 10.1128/aac.01285-13
PMC: PMC3837853
OpenAlex: W2148090354
Cited by: 366
References: 18
Citations by year: 2026: 31 · 2025: 26 · 2024: 33 · 2023: 37 · 2022: 47 · 2021: 22 · 2020: 20 · 2019: 26 · 2018: 26 · 2017: 38 · 2016: 19 · 2015: 25 · 2014: 14 · 2013: 1
FWCI: 15.26
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Antimicrobial Agents and Chemotherapy (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Keywords: respiratory syncytial virus, pharmacokinetics, extended half-life, clearance, amino acid substitutions, antidrug antibodies, drug safety, healthy volunteers
MeSH terms: Adult, Antiviral Agents, Double-Blind Method, Female, Half-Life, Humans, Immunoglobulin Fc Fragments, Injections, Intravenous, Male, Metabolic Clearance Rate, Drugs, Investigational, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks